Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

被引：0

作者：

Khan, Ali Younas ^{[1
]}

Iftikhar, Nimra ^{[1
]}

Ijaz, Awais ^{[1
]}

Tariq, Muhammad Junaid ^{[1
]}

Jamil, Faiza ^{[1
]}

Akbar, Arshia ^{[1
]}

Qureshi, Anum ^{[2
]}

Jose, Jemin Aby ^{[1
]}

Kamal, Ahmad ^{[1
]}

Abu Zar, Muhammad ^{[1
]}

Shafqat, Madeeha ^{[1
]}

Selene, Insija Ilyas ^{[1
]}

Aslam, Shehroz ^{[1
]}

Anwer, Faiz ^{[1
,3
]}

机构：

[1] Univ Arizona, Div Hematol & Oncol, Dept Med, Tucson, AZ USA

[2] Univ Arizona, Div Hematol & Oncol, Dept Med, Woodbridge, VA USA

[3] Cleveland Clin, Taussig Canc Ctr, Med Oncol, Dept Hematol, Cleveland, OH 44106 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-115867

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5484

引用

页数：4

共 50 条

[41] Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors
Brianna E. Vaa
Ayalew Tefferi
Naseema Gangat
Animesh Pardanani
Terra L. Lasho
Christy M. Finke
Alexandra P. Wolanskyj
Annals of Hematology, 2016, 95 : 1185 - 1189
[42] ALTERNATING USE OF DIFFERENT JAK1/JAK2 INHIBITORS, A POSSIBLE THERAPEUTIC STRATEGY USEFUL IN PRIMARY MYELOFIBROSIS: A CASE REPORT
Gutierrez, Lopez de Ocariz X.
Vera, Guerrero E.
Carreno, Gomez-Tarragona G.
Buendia, Urena B.
De Nicolas, Sol R.
Hidalgo, Soto M.
Lopez, Munoz N.
Zamanillo, Herreros, I
Iniguez, Garcia R.
Poza, Santaella M.
Ayala, Diaz R.
Martinez, Lopez J.
HAEMATOLOGICA, 2020, 105 : 395 - 395
[43] SYMPTOMS, RISK CLASSIFICATION, AND SPLEEN SIZE IN JAK2 INHIBITOR-NAIVE MYELOFIBROSIS: IMPLICATIONS FOR JAK2 INHIBITOR TREATMENT
Scherber, R.
Dueck, A.
Geyer, H.
Kosiorek, H.
Kiladjian, J. J.
Slot, S.
Zweegman, S.
Boekhorst, P.
Schouten, H.
Sackmann, F.
Fuentes, A.
Hernandez-Maraver, D.
Pahl, H.
Stegelmann, F.
Doehner, K.
Bonatz, K.
Reiter, A.
Boyer, F.
Etienne, G.
Ianotto, J. C.
Ranta, D.
Roy, L.
Cahn, J. Y.
Harrison, C.
Radia, D.
Muxi, P.
Maldonado, N.
Besses, C.
Cervantes, F.
Johansson, P.
Barosi, G.
Vannucchi, A.
Passamonti, F.
Andreasson, B.
Samuelsson, J.
Birgegard, G.
Sun, X.
Xu, J.
Zhang, P.
Xu, Z.
Barbui, T.
Barbui, T.
Senyak, Z.
Grieshammer, M.
Rambaldi, A.
Ferrari, M.
Lehmann, T.
Mesa, R.
HAEMATOLOGICA, 2016, 101 : 557 - 558
[44] JAK2 INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
Tefferi, A.
ANNALS OF ONCOLOGY, 2010, 21 : 20 - 21
[45] JAK-2 inhibitors and allogeneic transplant in myelofibrosis
Patriarca, Francesca
Sperotto, Alessandra
De Marchi, Roberta
Perali, Giulia
Cigana, Chiara
Lazzarotto, Davide
Fanin, Renato
DRUGS AND CELL THERAPIES IN HEMATOLOGY, 2015, 3 (04): : 237 - 246
[46] Targeting myeloproliferative diseases with JAK2 inhibitors
Markovtsov, Vadim
Yu, Diane
Gelman, Marina
Lang, Wayne
Taylor, Vanessa C.
Huynh, Stacey
Frances, Roy
Fang, Shilling
McLaughlin, John
Bhamidipati, Sohasekhar
Clough, Jeffrey
Singh, Rajinder
Park, Gary
Sweeney, David
Tonkin, Elizabeth
Bahjat, Rena
Chang, Betty
Pine, Polly
Daniel, Ruby
Payan, Donald G.
Holland, Sacha
Hitoshi, Yasurnichi
BLOOD, 2007, 110 (11) : 1039A - 1039A
[47] Update on JAK2 inhibitors in myeloproliferative neoplasm
Chan, Daniel
Koren-Michowitz, Maya
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2011, 2 (02) : 61 - 71
[48] JAK2 kinase inhibitors and myeloproliferative disorders
Chen, Andrew T.
Prchal, Josef T.
CURRENT OPINION IN HEMATOLOGY, 2010, 17 (02) : 110 - 116
[49] JAK2 inhibitors in the treatment of myeloproliferative neoplasms
Tibes, Raoul
Bogenberger, James M.
Geyer, Holly L.
Mesa, Ruben A.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (12) : 1755 - 1774
[50] JAK2 inhibitors and their impact in myeloproliferative neoplasms
Geyer, Holly L.
Tibes, Raoul
Mesa, Ruben A.
HEMATOLOGY, 2012, 17 : S129 - S132

← 1 2 3 4 5 →